Lachlan Hanbury Brown

Stock Analyst at William Blair

(2.56)
# 3,311
Out of 4,683 analysts
135
Total ratings
51.4%
Success rate
1.8%
Average return

Stocks Rated by Lachlan Hanbury Brown

Harrow
Aug 20, 2026
Maintained: Buy
Price Target: n/a
Current: $39.33
Upside: -
Surrozen
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $23.71
Upside: +115.10%
Ocular Therapeutix
Aug 17, 2026
Maintained: Buy
Price Target: n/a
Current: $10.77
Upside: -
ARS Pharmaceuticals
Aug 14, 2026
Maintained: Buy
Price Target: n/a
Current: $6.03
Upside: -
Tarsus Pharmaceuticals
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $70.65
Upside: -
Eupraxia Pharmaceuticals Inc.
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $10.28
Upside: -
LENZ Therapeutics
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $4.78
Upside: -
Kalaris Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: n/a
Current: $4.08
Upside: -
Viridian Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $24.26
Upside: -
Solid Biosciences
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $9.72
Upside: -
Maintained: Buy
Price Target: n/a
Current: $11.74
Upside: -